BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34261797)

  • 1. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
    Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
    Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of
    Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
    Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
    Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
    [No Abstract]   [Full Text] [Related]  

  • 4. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
    Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
    Magee K; Marsh IR; Turek MM; Grudzinski J; Aluicio-Sarduy E; Engle JW; Kurzman ID; Zuleger CL; Oseid EA; Jaskowiak C; Albertini MR; Esbona K; Bednarz B; Sondel PM; Weichert JP; Morris ZS; Hernandez R; Vail DM
    PLoS One; 2021; 16(8):e0255798. PubMed ID: 34383787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
    Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
    Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Hernandez R; Walker KL; Grudzinski JJ; Aluicio-Sarduy E; Patel R; Zahm CD; Pinchuk AN; Massey CF; Bitton AN; Brown RJ; Sondel PM; Morris ZS; Engle JW; Capitini CM; Weichert JP
    Commun Biol; 2019; 2():79. PubMed ID: 30820474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma.
    Li M; Liu D; Lee D; Cheng Y; Baumhover NJ; Marks BM; Sagastume EA; Ballas ZK; Johnson FL; Morris ZS; Schultz MK
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359580
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hernandez R; Grudzinski JJ; Aluicio-Sarduy E; Massey CF; Pinchuk AN; Bitton AN; Patel R; Zhang R; Rao AV; Iyer G; Engle JW; Weichert JP
    J Nucl Med; 2020 Aug; 61(8):1187-1194. PubMed ID: 31862799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
    O'Leary KA; Bates AM; Jin WJ; Burkel BM; Sriramaneni RN; Emma SE; Nystuen EJ; Sumiec EG; Ponik SM; Morris ZS; Schuler LA
    Breast Cancer Res; 2023 Jun; 25(1):68. PubMed ID: 37312163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin α
    Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
    Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Characterization of
    Grudzinski JJ; Hernandez R; Marsh I; Patel RB; Aluicio-Sarduy E; Engle J; Morris Z; Bednarz B; Weichert J
    J Nucl Med; 2019 Nov; 60(11):1622-1628. PubMed ID: 30954941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
    Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
    Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment.
    Kerr CP; Grudzinski JJ; Nguyen TP; Hernandez R; Weichert JP; Morris ZS
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
    Bellavia MC; Patel RB; Anderson CJ
    J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
    Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
    J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
    Zboralski D; Osterkamp F; Christensen E; Bredenbeck A; Schumann A; Hoehne A; Schneider E; Paschke M; Ungewiss J; Haase C; Robillard L; Simmons AD; Harding TC; Nguyen M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2621-2635. PubMed ID: 37086273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.
    Clark PA; Sriramaneni RN; Jin WJ; Jagodinsky JC; Bates AM; Jaquish AA; Anderson BR; Le T; Lubin JA; Chakravarty I; Arthur IS; Heinze CM; Guy EI; Kler J; Klar KA; Carlson PM; Kim KM; Kuo JS; Morris ZS
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
    Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
    Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.